Compare · ABT vs QURE
ABT vs QURE
Side-by-side comparison of Abbott Laboratories (ABT) and uniQure N.V. (QURE): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABT and QURE operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- ABT is the larger of the two at $200.95B, about 56.7x QURE ($3.54B).
- Over the past year, ABT is down 11.8% and QURE is up 222.7% - QURE leads by 234.4 points.
- ABT has been more active in the news (8 items in the past 4 weeks vs 2 for QURE).
- ABT has more recent analyst coverage (25 ratings vs 24 for QURE).
- Company
- Abbott Laboratories
- uniQure N.V.
- Price
- $116.11-0.50%
- $51.02+7.45%
- Market cap
- $200.95B
- $3.54B
- 1M return
- +11.04%
- +33.51%
- 1Y return
- -11.76%
- +222.68%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2014
- News (4w)
- 8
- 2
- Recent ratings
- 25
- 24
Abbott Laboratories
Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded in 1888 and is based in North Chicago, Illinois.
uniQure N.V.
uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease; AMT-060, which is in Phase I/II clinical trial for the treatment of hemophilia B; AMT-180 for the treatment of hemophilia A; AMT-190, an IV-administered adeno-associated virus (AAV) 5-based gene therapy for the treatment of Fabry disease; and AMT-150, a one-time, intrathecally-administered, AAV gene therapy for treating spinocerebellar ataxia type 3. The company has collaboration and license agreements with Bristol Myers-Squibb Company; Gen-X; and Synpromics Limited. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
Latest ABT
- Abbott receives FDA authorization for world's first dual glucose-ketone sensing technology for people with diabetes
- Abbott Laboratories filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
- Abbott reaches agreements to resolve a portion of litigation involving its specialty formulas for preterm infants
- Abbott and NACHC launch nationwide Food for Health initiative to make nutritious food a core part of healthcare
- EXECUTIVE VICE PRESIDENT Morrone Louis H. sold $642,506 worth of Common shares without par value (5,850 units at $109.83), decreasing direct ownership by 8% to 70,724 units (SEC Form 4)
- Abbott Labs upgraded by Wolfe Research with a new price target
- Abbott and Big Ten bring back 'We Give Blood' as U.S. faces blood supply crisis
- Abbott and Google launch first-of-its-kind partnership to transform everyday health through glucose insights and AI
- SEC Form 10-Q filed by Abbott Laboratories
- FDA Approves Freenome’s SimpleScreen™ CRC Blood-Based Screening Test; Abbott to Commercialize in the U.S.
Latest QURE
- Amendment: SEC Form SCHEDULE 13G/A filed by uniQure N.V.
- SEC Form SCHEDULE 13G filed by uniQure N.V.
- uniQure upgraded by Wolfe Research with a new price target
- SEC Form S-8 filed by uniQure N.V.
- SEC Form 10-Q filed by uniQure N.V.
- uniQure N.V. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- uniQure Announces Second Quarter 2026 Financial Results and Provides Company Update
- uniQure to Announce Second Quarter 2026 Financial Results
- SEC Form SCHEDULE 13G filed by uniQure N.V.
- CEO, Managing Director Kapusta Matthew C exercised 21,082 units of Ordinary Shares at a strike of $19.39 and sold $952,051 worth of Ordinary Shares (21,082 units at $45.16) as part of a pre-agreed trading plan (SEC Form 4)